DrugPatentWatch Database Preview
King Pharms Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for KING PHARMS, and when can generic versions of KING PHARMS drugs launch?
KING PHARMS has twenty-seven approved drugs.
There are six US patents protecting KING PHARMS drugs.
There are seventy-three patent family members on KING PHARMS drugs in thirty-two countries and nine supplementary protection certificates in six countries.
Summary for King Pharms
| International Patents: | 73 |
| US Patents: | 6 |
| Tradenames: | 25 |
| Ingredients: | 23 |
| NDAs: | 27 |
Drugs and US Patents for King Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-012 | May 25, 2001 | DISCN | Yes | No | 6,555,581 | Start Trial | Start Trial | ||||
| King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-004 | May 25, 2001 | AB1,AB3 | RX | Yes | No | 6,555,581 | Start Trial | Start Trial | |||
| King Pharms Llc | INTAL | cromolyn sodium | AEROSOL, METERED;INHALATION | 018887-001 | Dec 5, 1985 | DISCN | No | No | Start Trial | Start Trial | |||||
| King Pharms | APOGEN | gentamicin sulfate | INJECTABLE;INJECTION | 062289-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | Start Trial | Start Trial | |||||
| King Pharms Llc | ALTACE | ramipril | CAPSULE;ORAL | 019901-001 | Jan 28, 1991 | AB | RX | Yes | No | 7,368,469 | Start Trial | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for King Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| King Pharms Llc | ALTACE | ramipril | CAPSULE;ORAL | 019901-004 | Jan 28, 1991 | 5,061,722 | Start Trial |
| King Pharms Llc | INTAL | cromolyn sodium | SOLUTION;INHALATION | 018596-001 | May 28, 1982 | 3,686,412 | Start Trial |
| King Pharms Llc | ALTACE | ramipril | CAPSULE;ORAL | 019901-003 | Jan 28, 1991 | 5,403,856 | Start Trial |
| King Pharms Llc | AVINZA | morphine sulfate | CAPSULE, EXTENDED RELEASE;ORAL | 021260-002 | Mar 20, 2002 | 6,066,339 | Start Trial |
| King Pharms Llc | INTAL | cromolyn sodium | AEROSOL, METERED;INHALATION | 018887-001 | Dec 5, 1985 | 3,686,412 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for KING PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Capsules | 30 mg, 60 mg, 90 mg and 120 mg | ➤ Subscribe | 2007-06-04 |
| ➤ Subscribe | Tablets | 800 mg | ➤ Subscribe | 2004-11-04 |
| ➤ Subscribe | Extended-release Capsules | 45 mg and 75 mg | ➤ Subscribe | 2009-07-30 |
International Patents for King Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 03013441 | Start Trial |
| European Patent Office | 1216038 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2007094825 | Start Trial |
| Croatia | P20020170 | Start Trial |
| Turkey | 200200515 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for King Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1539166 | 13C0062 | France | Start Trial | PRODUCT NAME: (A) DEXTROMETHORPHAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRATE DE DEXTROMETHORPHAN ET EN PARTICULIER LE MONOHYDRATE DE BROMHYDRATE DE DEXTROMETHORPHAN (B) QUINIDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE SULFATE DE QUINIDINE EN PARTICULIER LE DIHYDRATE DE SULFATE DE QUINIDINE; REGISTRATION NO/DATE: EU/1/13/833/001-003 20130626 |
| 1539166 | SPC/GB13/070 | United Kingdom | Start Trial | PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, E.G. Q; REGISTERED: UK EU/1/13/833 20130626 |
| 1539166 | 92323 | Luxembourg | Start Trial | PRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624 |
| 0265685 | SPC/GB98/047 | United Kingdom | Start Trial | PRODUCT NAME: COMBINATIONS OF RAMIPRIL, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND FELODIPINE, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: SE 13596 19970919; SE 13597 19970919; UK 00017/0402 19980825; UK 00017/0403 19980825 |
| 0265685 | C980030 | Netherlands | Start Trial | PRODUCT NAME: FELODIPINE, DESGEWENST IN DE VORM VAN FYSIOLOGISCH AANVAARDBAAR ZOUT, EN (2S, 3AS, 6AS)-1-[(S)-N-[(S)-1-CARBOXY-3-FENYLPROPYL]A LANYL]OCTAHYDROCYCLOPENTA[B]-PYRROOL-2-CARBONZUUR (RAMIPRILAAT) , DESGEWENST IN DE VORM VAN EEN .....ZIE VERDER IN HET DOSSIER; NAT. REGISTRATION NO/ DATE: RVG 22449, RVG 22450 19980618; FIRST REGISTRATION: SE 13596, 13597 19970919 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
